ArticleCancer informatics2026
GATES: A Lightweight Tool Automating Pathogenic Variant Discovery From Raw Whole-Exome Sequencing Data.
Article in Cancer informatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Whole-exome sequencing is a widely used technology to identify pathogenic variants in cancer. Although sequencing itself has become increasingly accessible, downstream analysis remains computationally complex, presenting a challenge for many researchers. Existing pipelines lack integrated support for somatic and germline variant detection and still require significant computational resources. Methods: We developed GATES (GATK Automated Tool for Exome Sequencing), a lightweight pipeline that automates data preprocessing, variant calling, and variant annotation directly from raw paired-end FASTQ files through a simplified command-line interface. GATES implements the GATK Best Practices for somatic and germline variant detection and leverages Ensembl's Variant Effect Predictor for functional annotation, outputting the results in a human-readable tab-separated values (TSV) file. We evaluated the pipeline's performance using the SEQC-II benchmarking dataset and demonstrated its application using a clinical sample harboring known pathogenic germline and somatic variants. Results: GATES was run on a standard laptop and performed end-to-end variant analysis for each sample within a few hours. In benchmarking with SEQC-II samples, germline and tumor-normal somatic variant calling modes demonstrated high concordance with their respective truth sets. Tumor-only somatic mode showed decreased accuracy, consistent with expected germline contamination. GATES demonstrated high performance across various hardware configurations and compared to the established nf-core/sarek pipeline. GATES further successfully performed somatic and germline analysis of a >100X clinical sample in under 7 hours. Importantly, the pipeline accurately distinguished the known Conclusion: By lowering the technical barriers to exome sequencing analysis, GATES provides a practical solution for pathogenic variant discovery for researchers both with and without computational expertise.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.